441067-49-8

Basic information

• Product Name: (4S)-4-hydroxy-L-proline hydrochloride
• Synonyms: (4S)-4-hydroxy-L-proline hydrochloride;L-Proline, 4-hydroxy-,hydrochloride, cis-;(2s,4S)-4-hydroxy-L-proline hydrochloride;Cis-4-hydroxy-L-prolineMonohydrochloride;L-Proline,4-hydroxy-,hydrochloride(1:1),(4S)-;H-cis-Hyp-OH·HCl;cis-4-Hydroxypyrrolidine-2-carboxylic acid hydrochloride;L-Proline, 4-hydroxy-, hydrochloride, (4S)-
• CAS NO: 441067-49-8
• Molecular Formula: C5H10ClNO3
• Molecular Weight: 167.5908
• EINECS: 1592732-453-0
• Mol File: 441067-49-8.mol
• Article Data: 16

Chemical Properties

• Boiling Point: 368.6°C at 760 mmHg
• Flash Point: 176.7°C
• Appearance: /
• Vapor Pressure: 6.22E-07mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: (4S)-4-hydroxy-L-proline hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (4S)-4-hydroxy-L-proline hydrochloride(441067-49-8)
• EPA Substance Registry System: (4S)-4-hydroxy-L-proline hydrochloride(441067-49-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 441067-49-8(Hazardous Substances Data)

Usage

General Description

(4S)-4-hydroxy-L-proline hydrochloride is a chemical compound with the molecular formula C5H9NO3?HCl. It is a derivative of the amino acid proline, consisting of a hydroxy group attached to the fourth carbon of the proline molecule. (4S)-4-hydroxy-L-proline hydrochloride is commonly used in the synthesis of peptide-based drugs and pharmaceuticals, as well as in the production of biologically active compounds and natural products. Its hydrochloride form makes it more stable and soluble in water, allowing for easier handling and administration in various applications. Additionally, (4S)-4-hydroxy-L-proline hydrochloride has been studied for its potential biological and pharmacological properties, including its role in the modulation of collagen synthesis and connective tissue repair.

InChI:InChI=1/C5H9NO3.ClH/c7-3-1-4(5(8)9)6-2-3;/h3-4,6-7H,1-2H2,(H,8,9);1H/t3-,4-;/m0./s1

Upstream product

• 51-35-4 4R-4-hydroxyproline 
• 135042-17-0 (2R,4S)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 
• 364750-80-1 (2S,4R)-1-[(tert-butoxy)carbonyl]-4-methylpyrrolidine-2-carboxylic acid 
• 138512-74-0 1-tert-butyl 2-methyl (2S,4R)-4-methylpyrrolidine-1,2-dicarboxylate 
• 444313-67-1 (1R,4R)-5-acetyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-one 
• 13726-69-7 (2S,4R)-4-hydroxy-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid 

Downstream Products

• 114676-55-0 (2R,4S)-methyl 4-azido-1-benzylpyrrolidine-2-carboxylate 
• 1611481-16-3 (2R,4R)-methyl 4-azido-1-benzylpyrrolidine-2-carboxylate 
• 74844-91-0 1-tert-butyl 2-methyl (2S,4R)-4-hydroxy-1,2-pyrrolidinedicarboxylate 

Relevant articles and documents

A sub-milligram-synthesis protocol for in vitro screening of HDAC11 inhibitors

This work demonstrated the high efficiency of a sub-milligram-synthesis based medicinal chemistry method. Totally 72 compounds, consisting a tri-substituted pyrrolidine core, were prepared. Around 0.1 mg of each compound was solid-phase synthesized. Based on the additive property of UV absorptions of unconjugated chromophores of a molecule, these compounds were quantified by UV measurement. A hit, whose IC50 value was 1.2 μM in HDAC11 inhibition assays, highlights the applicability of the approach reported here in future optimization works.

CARBOHYDRATE CONJUGATED RNA AGENTS AND PROCESS FOR THEIR PREPARATION

This disclosure relates to an improved process for the preparation of carbohydrate conjugates. The disclosure also relates to carbohydrate conjugated iRNA agents comprising these carbohydrate conjugates, which have improved purity and are advantageous for the in vivo delivery of the iRNA agents.

Design and stereoselective synthesis of four peptide nucleic acid monomers with cyclic structures in backbone

Four isomers of the monomer of peptide nucleic acid (PNA) were derived from (2S,4R)-4-hydroxyproline; they had different stereochemistries at the C 2 and C4 positions in the pyrrolidine ring. These different backbone conformations corresponding to four different stereochemistries were realized through a combination of inversions at the C2 and the C4 positions in pyrrolidine ring. The obtained backbone frameworks were reacted with N-benzoyl thymine to give the corresponding PNA monomers. Spectroscopic comparison of the resultant monomers confirmed their stereochemistries.